Topic: acute myeloid leukemia
Weeks after a Venclexta-chemo combo flopped a confirmatory trial in acute myeloid leukemia, a second combo hit its marks in a separate study.
AbbVie and Roche were looking for a trial win to confirm blood cancer drug Venclexta's FDA approval in AML. Instead, the pair got a setback.
The FDA rejects Daiichi's quizarinib and Glenmark's Ryaltris; Takeda sets a deadline for its U.S. headquarters move; JLABS Shanghai launches.
Takeda releases first post-Shire guidance; Indian generics makers are named in a price-fixing suit; Daiichi's quizartinib fails at FDA.
Daiichi inks $6.9 billion ADC deal with AZ, appoints new CEO; Keytruda nabs first-line lung cancer nod in China.
Astellas is looking to snap up share with Xospata before an AML rival hits the scene, and new survival data could help speed that process along.
A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.
Astellas will likely soon be joined by Daiichi in relapsed/refractory FLT3-mutated AML, and both have eyes on Novartis' Rydapt.
Make that four drug approvals for Pfizer’s oncology unit in less than two months, a welcome streak for the pharma giant as new generics loom.
AbbVie and Roche’s Venclexta is leaving familiar territory with its latest nod. And to establish itself on its new turf, it’ll have to duke it out with some Big Pharma rivals.